96 shRNAs designed for maximal coverage of HIV-1 variants.
Identifieur interne : 002014 ( PubMed/Corpus ); précédent : 002013; suivant : 00201596 shRNAs designed for maximal coverage of HIV-1 variants.
Auteurs : Glen John Mcintyre ; Jennifer Lynne Groneman ; Yi-Hsin Yu ; Angel Jaramillo ; Sylvie Shen ; Tanya Lynn ApplegateSource :
- Retrovirology [ 1742-4690 ] ; 2009.
English descriptors
- KwdEn :
- Cell Line, Conserved Sequence, Genes, Reporter, Genetic Therapy (methods), Genetic Variation, HIV Infections (genetics), HIV Infections (therapy), HIV-1 (drug effects), HIV-1 (genetics), Humans, Inverted Repeat Sequences, Molecular Sequence Data, RNA Interference, RNA, Small Interfering (genetics), RNA, Small Interfering (pharmacology), RNA, Viral (antagonists & inhibitors), RNA, Viral (genetics), Sequence Analysis, DNA (methods), Virus Inactivation (drug effects).
- MESH :
- chemical , antagonists & inhibitors : RNA, Viral.
- chemical , genetics : RNA, Small Interfering, RNA, Viral.
- drug effects : HIV-1, Virus Inactivation.
- genetics : HIV Infections, HIV-1.
- methods : Genetic Therapy, Sequence Analysis, DNA.
- chemical , pharmacology : RNA, Small Interfering.
- therapy : HIV Infections.
- Cell Line, Conserved Sequence, Genes, Reporter, Genetic Variation, Humans, Inverted Repeat Sequences, Molecular Sequence Data, RNA Interference.
Abstract
The RNA interference (RNAi) pathway is a mechanism of gene-suppression with potential gene therapy applications for treating viral disease such as HIV-1. The most suitable inducer of RNAi for this application is short hairpin RNA (shRNA) although it is limited to suppressing a single target. A successful anti-HIV-1 therapy will require combinations of multiple highly active, highly conserved shRNAs to adequately counter the emergence of resistant strains.
DOI: 10.1186/1742-4690-6-55
PubMed: 19497094
Links to Exploration step
pubmed:19497094Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">96 shRNAs designed for maximal coverage of HIV-1 variants.</title><author><name sortKey="Mcintyre, Glen John" sort="Mcintyre, Glen John" uniqKey="Mcintyre G" first="Glen John" last="Mcintyre">Glen John Mcintyre</name><affiliation><nlm:affiliation>Johnson and Johnson Research Pty Ltd, Australian Technology Park, Eveleigh, NSW, Australia. glen@madebyglen.com</nlm:affiliation></affiliation></author><author><name sortKey="Groneman, Jennifer Lynne" sort="Groneman, Jennifer Lynne" uniqKey="Groneman J" first="Jennifer Lynne" last="Groneman">Jennifer Lynne Groneman</name></author><author><name sortKey="Yu, Yi Hsin" sort="Yu, Yi Hsin" uniqKey="Yu Y" first="Yi-Hsin" last="Yu">Yi-Hsin Yu</name></author><author><name sortKey="Jaramillo, Angel" sort="Jaramillo, Angel" uniqKey="Jaramillo A" first="Angel" last="Jaramillo">Angel Jaramillo</name></author><author><name sortKey="Shen, Sylvie" sort="Shen, Sylvie" uniqKey="Shen S" first="Sylvie" last="Shen">Sylvie Shen</name></author><author><name sortKey="Applegate, Tanya Lynn" sort="Applegate, Tanya Lynn" uniqKey="Applegate T" first="Tanya Lynn" last="Applegate">Tanya Lynn Applegate</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19497094</idno><idno type="pmid">19497094</idno><idno type="doi">10.1186/1742-4690-6-55</idno><idno type="wicri:Area/PubMed/Corpus">002014</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002014</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">96 shRNAs designed for maximal coverage of HIV-1 variants.</title><author><name sortKey="Mcintyre, Glen John" sort="Mcintyre, Glen John" uniqKey="Mcintyre G" first="Glen John" last="Mcintyre">Glen John Mcintyre</name><affiliation><nlm:affiliation>Johnson and Johnson Research Pty Ltd, Australian Technology Park, Eveleigh, NSW, Australia. glen@madebyglen.com</nlm:affiliation></affiliation></author><author><name sortKey="Groneman, Jennifer Lynne" sort="Groneman, Jennifer Lynne" uniqKey="Groneman J" first="Jennifer Lynne" last="Groneman">Jennifer Lynne Groneman</name></author><author><name sortKey="Yu, Yi Hsin" sort="Yu, Yi Hsin" uniqKey="Yu Y" first="Yi-Hsin" last="Yu">Yi-Hsin Yu</name></author><author><name sortKey="Jaramillo, Angel" sort="Jaramillo, Angel" uniqKey="Jaramillo A" first="Angel" last="Jaramillo">Angel Jaramillo</name></author><author><name sortKey="Shen, Sylvie" sort="Shen, Sylvie" uniqKey="Shen S" first="Sylvie" last="Shen">Sylvie Shen</name></author><author><name sortKey="Applegate, Tanya Lynn" sort="Applegate, Tanya Lynn" uniqKey="Applegate T" first="Tanya Lynn" last="Applegate">Tanya Lynn Applegate</name></author></analytic><series><title level="j">Retrovirology</title><idno type="eISSN">1742-4690</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell Line</term><term>Conserved Sequence</term><term>Genes, Reporter</term><term>Genetic Therapy (methods)</term><term>Genetic Variation</term><term>HIV Infections (genetics)</term><term>HIV Infections (therapy)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (genetics)</term><term>Humans</term><term>Inverted Repeat Sequences</term><term>Molecular Sequence Data</term><term>RNA Interference</term><term>RNA, Small Interfering (genetics)</term><term>RNA, Small Interfering (pharmacology)</term><term>RNA, Viral (antagonists & inhibitors)</term><term>RNA, Viral (genetics)</term><term>Sequence Analysis, DNA (methods)</term><term>Virus Inactivation (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Small Interfering</term><term>RNA, Viral</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Virus Inactivation</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV Infections</term><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Genetic Therapy</term><term>Sequence Analysis, DNA</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>RNA, Small Interfering</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line</term><term>Conserved Sequence</term><term>Genes, Reporter</term><term>Genetic Variation</term><term>Humans</term><term>Inverted Repeat Sequences</term><term>Molecular Sequence Data</term><term>RNA Interference</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The RNA interference (RNAi) pathway is a mechanism of gene-suppression with potential gene therapy applications for treating viral disease such as HIV-1. The most suitable inducer of RNAi for this application is short hairpin RNA (shRNA) although it is limited to suppressing a single target. A successful anti-HIV-1 therapy will require combinations of multiple highly active, highly conserved shRNAs to adequately counter the emergence of resistant strains.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19497094</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-4690</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2009</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>Retrovirology</Title><ISOAbbreviation>Retrovirology</ISOAbbreviation></Journal><ArticleTitle>96 shRNAs designed for maximal coverage of HIV-1 variants.</ArticleTitle><Pagination><MedlinePgn>55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1742-4690-6-55</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The RNA interference (RNAi) pathway is a mechanism of gene-suppression with potential gene therapy applications for treating viral disease such as HIV-1. The most suitable inducer of RNAi for this application is short hairpin RNA (shRNA) although it is limited to suppressing a single target. A successful anti-HIV-1 therapy will require combinations of multiple highly active, highly conserved shRNAs to adequately counter the emergence of resistant strains.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We calculated the percentage conservations of 8, 846 unique 19 nucleotide HIV-1 targets amongst 37, 949 HIV-1 gene sequence fragments containing 24.8 million 19 mers. We developed a novel method of determining conservation in 'profile' sets of 5 overlapping 19 mer sequences (covering 23 nucleotides in total) to ensure that the intended conservation of each shRNA would be unaffected by possible variations in shRNA processing. Ninety six of the top ranking targets from 22 regions were selected based on conservation profiles, predicted activities, targets and specific nucleotide inclusion/exclusion criteria. We constructed 53 shRNAs with 20 bp stems and 43 shRNAs with 21 bp stems which we tested and ranked using fluorescent reporter and HIV-1 expression assays. Average suppressive activities ranged from 71 - 75%, with 65 hairpins classed as highly active (> 75% activity). Overall we found little difference in activities from minor changes in stem length (20 cf. 21), or between neighboring targets differing by a single nucleotide in start position. However, there were several exceptions which suggest that all sequences, irrespective of similarities in target site or design, may be useful candidates. We encountered technical limitations with GFP reporter assays when the target domain was long and or when the distance between the target site and fusion junction was large. Assay performance was improved by dividing large targets into several shorter domains.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In summary, our novel selection process resulted in a large panel of highly active shRNAs spanning the HIV-1 genome, representing excellent candidates for use in multiple shRNA gene therapies. Our core selection method ensuring maximal conservation in the processed product(s) is also widely applicable to other shRNA applications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Glen John</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Johnson and Johnson Research Pty Ltd, Australian Technology Park, Eveleigh, NSW, Australia. glen@madebyglen.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groneman</LastName><ForeName>Jennifer Lynne</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yi-Hsin</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Jaramillo</LastName><ForeName>Angel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Applegate</LastName><ForeName>Tanya Lynn</ForeName><Initials>TL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Retrovirology</MedlineTA><NlmUniqueID>101216893</NlmUniqueID><ISSNLinking>1742-4690</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055029" MajorTopicYN="Y">Inverted Repeat Sequences</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="Y">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038301" MajorTopicYN="N">Virus Inactivation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>03</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>06</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19497094</ArticleId><ArticleId IdType="pii">1742-4690-6-55</ArticleId><ArticleId IdType="doi">10.1186/1742-4690-6-55</ArticleId><ArticleId IdType="pmc">PMC2698899</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Retrovirology. 2007;4:80</Citation><ArticleIdList><ArticleId IdType="pubmed">17996047</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Biotechnol. 2006;6:1</Citation><ArticleIdList><ArticleId IdType="pubmed">16396676</ArticleId></ArticleIdList></Reference><Reference><Citation>J RNAi Gene Silencing. 2005 Oct 14;1(2):56-65</Citation><ArticleIdList><ArticleId IdType="pubmed">19771206</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Cell Biol. 2007 Apr;85(2):259-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17534408</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2002 May;20(5):500-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11981565</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Biotechnol. 2004 Sep;22(9):451-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15331225</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Jun;79(11):7050-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15890944</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 2005;392:73-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15644176</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2004;32(3):936-48</Citation><ArticleIdList><ArticleId IdType="pubmed">14769950</ArticleId></ArticleIdList></Reference><Reference><Citation>RNA. 2005 May;11(5):674-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15811921</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5515-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11960009</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6047-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11972060</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2005;33(2):796-804</Citation><ArticleIdList><ArticleId IdType="pubmed">15687388</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2002 May;20(5):497-500</Citation><ArticleIdList><ArticleId IdType="pubmed">11981564</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W448-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16845046</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2003 Aug 1;31(15):4417-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12888501</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ther. 2006 Mar;13(6):532-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16177819</ArticleId></ArticleIdList></Reference><Reference><Citation>RNA. 2002 Jun;8(6):842-50</Citation><ArticleIdList><ArticleId IdType="pubmed">12088155</ArticleId></ArticleIdList></Reference><Reference><Citation>RNA. 2007 Oct;13(10):1631-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17684233</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2005 May;6(5):376-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15852042</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Nov;77(21):11531-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14557638</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Rev. 2003 Jan-Mar;5(1):52-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12875108</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2005 Nov;37(11):1289-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16200064</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Sep 16;431(7006):371-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15372045</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2004 Mar;22(3):326-30</Citation><ArticleIdList><ArticleId IdType="pubmed">14758366</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2002 Jun;9(6):1327-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12086629</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2005 May 13;348(4):871-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15843019</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2003 Jun;4(6):457-67</Citation><ArticleIdList><ArticleId IdType="pubmed">12778125</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Methods. 2004 Nov;1(2):163-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16144086</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 1996 Oct;16(10):5801-10</Citation><ArticleIdList><ArticleId IdType="pubmed">8816494</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Oct 21;351(17):1772-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15496626</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 2005;392:371-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15644193</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Biotechnol. 2006;6:7</Citation><ArticleIdList><ArticleId IdType="pubmed">16433925</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2004 Jan 23;116(2):281-97</Citation><ArticleIdList><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1443-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11818553</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2005 May 13;348(4):883-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15843020</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Sep 2;309(5740):1519-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16141061</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Apr 19;296(5567):550-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11910072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Feb;79(3):1645-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15650190</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2008 May;26(5):578-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18438400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2003 Oct 17;115(2):199-208</Citation><ArticleIdList><ArticleId IdType="pubmed">14567917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2004;32(3):1154-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14966264</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2002 Nov 1;21(21):5875-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12411505</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Mar;78(5):2601-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14963165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2002 May;20(5):505-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11981566</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2004 Jul 9;118(1):57-68</Citation><ArticleIdList><ArticleId IdType="pubmed">15242644</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2005 Nov;37(11):1281-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16200065</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Bioinformatics. 2009;10 Suppl 1:S33</Citation><ArticleIdList><ArticleId IdType="pubmed">19208134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther. 2006 Dec;14(6):883-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16959541</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2001 Jan 18;409(6818):363-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11201747</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Struct Mol Biol. 2004 Mar;11(3):214-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14983173</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2003 Jul 1;31(13):3406-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12824337</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002014 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002014 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19497094
|texte= 96 shRNAs designed for maximal coverage of HIV-1 variants.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19497094" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |